AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05826587 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation & Exercise Prescription
Description: Standard, clinically indicated cardiac rehabilitation and exercise program. Approximately 30 to 40 minutes of aerobic exercise within a prescribed rating of perceived exertion (RPE 11-14) and/or target heart rate and approximately 15 to 20 minutes of both upper and lower body resistance exercise up to three times per week for up to at least 12 weeks. In addition, subjects are provided with home exercise instructions, and will be expected to exercise for 30 to 60 minutes at home.
Study NCT05826587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation & Exercise Prescription
Description: Standard, clinically indicated cardiac rehabilitation and exercise program. Approximately 30 to 40 minutes of aerobic exercise within a prescribed rating of perceived exertion (RPE 11-14) and/or target heart rate and approximately 15 to 20 minutes of both upper and lower body resistance exercise up to three times per week for up to at least 12 weeks. In addition, subjects are provided with home exercise instructions, and will be expected to exercise for 30 to 60 minutes at home.
Study NCT05826587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connected mHealth mobile application
Description: Mobile application that allows subjects to track their independent home exercise with the option of heart rate monitoring by connecting to an external heart rate monitoring device.
Study NCT05826587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connected mHealth mobile application
Description: Mobile application that allows subjects to track their independent home exercise with the option of heart rate monitoring by connecting to an external heart rate monitoring device.
Study NCT05922345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules
Description: AL2846 capsules is a multi-targeted small molecule receptor tyrosine kinase inhibitor.~TQB2450 Injection is an anti-programmed death-1 (PD-L1).
Study NCT05922345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQB2450 placebo, docetaxel injection, AL2846 matching placebo
Description: Docetaxel injection is a type of chemotherapy for treatment of different types of cancer.
Study NCT06120764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guided imagery
Description: The children in the experimental group will listen to the first part of the 'Guided Imagery CD' prepared by the Turkish Psychological Association for relaxation 30 minutes before the chemotherapy infusion starts. The suggestions given in the first part of the CD will help the patients relax and focus their attention on their breathing. Patients will be positioned in a supine or semi-fowler position and will listen to the CD with headphones from a laptop. Once the chemotherapy infusion starts, relaxing light background music with the sound of a river or sea will be played based on the patients' preference, and imagery will be applied to the patients. Patients will be encouraged to think of various images, such as imagining that the treatment is over, visualizing themselves as much healthier and recovering quickly, returning to their old life, and doing whatever they want to do first after recovery. If there is an object, person, event, situation, or food that will make them feel good,
Study NCT06491563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-179
Description: BRII-179 will be given via intramuscular injection
Study NCT06491563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-835 (VIR-2218)
Description: BRII-835 will be given via subcutaneous injection
Study NCT06491563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα will be given via subcutaneous injection
Study NCT05465499 — intervention group
Intervention type: PROCEDURE
Intervention: ERAS
Description: This study is a cross-sectional observational study by distributing questionnaires regarding the readiness to implement ERAS at Dr Soetomo General Hospital to the subjects, so there is no treatment whatsoever on the subjects.
Study NCT01170871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Study NCT06021795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound Treatment
Description: Customized sound audio track delivered via standard commercially available bone conduction headset
Study NCT05345613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Submucosal injection of standard solution including TXA during EMR procedure
Study NCT05345613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard
Description: Injection of standard solution
Study NCT04429100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: One novel MRI sequence, i.e. the quantitative imaging of macromolecular proton fraction (MPF), will be introduced into this study. MPF is defined as the relative amount of protons associated with macromolecules involved in magnetization exchange with free water protons. This parameter is independent of the pool model used for quantification and the pulse sequences used for data acquisition. Recent studies have found a strong association between MPF and collagen content in the fibrotic liver, indicating MPF is a potential biomarker of early-stage liver fibrosis.
Study NCT06577727 — intervention group
Intervention type: OTHER
Intervention: Gold standard blood test
Description: Blood test will measure haemoglobin and other parameters
Study NCT06577727 — intervention group
Intervention type: OTHER
Intervention: Imaging and videography of anatomical sites
Description: Images and videos of anatomical sites will be collected for AI to estimate iron status
Study NCT06578325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai dance meditation
Description: Thai dance meditation training program will be based on aerobic Thai dance exercise combined with Buddhist meditation. The participants will perform aerobic Thai dance meditation while concentrated on hand movements through counting the numbers 1 2 3 4 5 6 7 1 on the 1st round and continuing on the 2nd round, counting as 1 2 3 4 5 6 7 2.... Repeat for 8 rounds. Thai dance meditation will be conducted at mild to moderate intensity (40-60% heart rate reserve) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (50-60% heart rate reserve). In both phases the training will be performed foe 50 minutes, 3 times per week.
Study NCT06578325 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: No intervention
Study NCT05646264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine
Description: Agomepratine is added to a second-generation antipsychotic drug (olanzapine, aripiprazole, risperidone, etc.)
Study NCT04487756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg in 20 ML Injection
Description: - Induction (4 cycles, every 3 weeks): Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle)~- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks)
Study NCT04487756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADC Vaccine
Description: - Maintenance (only patients without PD after 4 induction cycles, up to PD): DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33.
Study NCT06118372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand Factor
Description: Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
Study NCT05408208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Injection of Methotrexate
Description: One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
Study NCT05408208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonid
Description: One lesion will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . another plaque will treated with Intralesional injection of distilled water as controed plaque Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
Study NCT05561270 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: White LED light
Description: Exposure to white LED light for 1-2 hours/day x 10 weeks
Study NCT05561270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green LED light
Description: Exposure to green LED light for 1-2 hours/day x 10 weeks
Study NCT06093113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alba - Youth in grief
Description: The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains five main sections: Learning, Self-assessment, Manage symptoms, Find support and a Personal space.
Study NCT01170871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT05703178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Pain Coping Skills Training
Description: The intervention is completed online, using a personal computer, tablet computer, or smartphone. It includes 8 interactive sessions, each of which teaches users a different pain coping skill. Participants are asked to practice these skills in their daily lives to manage pain and pain-related symptoms and problems. Each session takes 35 to 45 minutes to complete. Participants can take breaks during the sessions and review them at any time after completing them.
Study NCT05703178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
Study NCT05703178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants will receive their usual medical care and an educational booklet with information about Aromatase Inhibitors (AIs), side effects they cause including painful arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other AI side effects.
Study NCT05737381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Differential oxygen tension
Description: By culturing the embryos in a differential O2 set-up, changing the O2 tension from reduced (5% O2) to ultralow (2% O2) from day 3 to day 5 of embryo development in vitro, we mimic the physiological differential changes in O2 as the embryo migrate from the oviduct to the uterus and develops in vivo.
Study NCT06093113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control website
Description: The website will contain information about grief and grief reactions similar to some of the information given in the app.
Study NCT06516497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group using traditional method in long bone deformity correction
Description: Osteotomy will be performed from the deformity center after two coring wires are placed in the same plane from the proximal and distal of the determined osteotomy line to the femur or tibia of the patients in the control group with deformity. While the degree of deformity is corrected, the determination will be made after the amount of deformity determined preoperatively is determined visually.
Study NCT06516497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group using computer-aided sensors in long bone deformity correction
Description: After 2 wires are placed in the same plane from the proximal and distal parts of the osteotomy line determined on the deformed femur or tibia of patients who underwent general anesthesia during the surgery, motion sensors will be placed on the wires. Osteotomy will be performed on the bone with deformity from the deformity center. When correcting the degree of deformity, the detection will be performed after the correction is achieved by the amount of deformity determined preoperatively.
Study NCT06129344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage Group
Description: Manual Lymphatic Drainage Group:Performed by physiotherapists trained by Dr. Vodder School and licensed in Lymphatic Consolidation Detoxification Therapy (CDT). The patient's treatment posture is to lie down. First, start with the neck lymphatic drainage technique. After performing bilateral axillary lymph node activation and lymphatic valve contraction, the bilateral breast lymph fluid is drained to the bilateral lymph nodes. The time is about 20 minutes. Assist in removing milk from both breasts for 15 minutes each. Once a day for three consecutive days of treatment.
Study NCT06129344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy group
Description: Ultrasound therapy group: performed by a physical therapist. This study uses an ultrasonic therapy device (model: UTO US-750 Therapeutic Ultrasound), frequency: 1MHz, intensity set to 1.0 Watt/cm2, pulsed mode, duty cycle 100%, treatment time 2 5 minutes on each side, and then assist in removing the breast milk from both breasts for 15 minutes on each side. Once a day for three consecutive days of treatment.
Study NCT04541147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone solution or tablet (depending on age of patient) at 0.5mg/kg/day max of 8mg/day, administered on post-operative days 1,3,5,7.
Study NCT04541147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesics
Description: standardization of post-operative analgesics (narcotics and non-narcotic medication).~* Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~* Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~* Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)
Study NCT04541147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesics
Description: standardization of post-operative analgesics (narcotics and non-narcotic medication).~* Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~* Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~* Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)
Study NCT06636409 — intervention group
Intervention type: OTHER
Intervention: Collection of medical data
Description: A randomised selection of files to be analyzed will be conducted in each center to constitute a representative sample of liver transplanted patients. This represents 20% of the number of transplanted patients over the period 2008-2013 in the center, allowing a more in-depth analysis of the patients' medical records.
Study NCT06636461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microfragmented adipose tissue loaded on allograft
Description: microfragmented adipose tissue loaded on allograft on ridge preservation
Study NCT04487756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: - Induction (4 cycles, every 3 weeks): Carboplatin AUC 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle)
Study NCT06636461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microfragmented adipose tissue loaded on allograft
Description: microfragmented adipose tissue loaded on allograft on ridge preservation
Study NCT06635369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Periodontal Indices
Description: Saliva, serum and periodontal indexes were obtained from patients
Study NCT06378346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin
Description: 75mg orally daily
Study NCT06378346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glycyrrhizin
Description: 150mg orally daily
Study NCT06378346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: Participants will not receive any Glycyrrhizin
Study NCT05720949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genicular Nerve Block with bupivacaine and preservative free dexamethasone
Description: A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee.~The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius.~Bupivacaine - Drug class: Sodium channel blocker~Dexamethasone - Drug class: Glucocorticoid
Study NCT05893758 — intervention group
Intervention type: DEVICE
Intervention: The Cera™ PFO Occluder
Description: The Cera™ PFO Occluder is a percutaneous, transcatheter closure device for the non-surgical closure of Patent Foramen Ovale (PFO).
Study NCT06043323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Given by IV (vein)
Study NCT06043323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)
Study NCT06043323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV (vein)
Study NCT06043323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given by IV (vein)
Study NCT06043323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Given by IV (vein)
Study NCT06043323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Given by IV (vein)
Study NCT04559789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindMate + Health Coaching
Description: The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack.
Study NCT04559789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education materials delivered electronically
Study NCT05801536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCONE
Description: This is a noninvasive (nonsurgical) electrical neuromodulation device to reactivate and retrain the neurons and neural networks in the spinal cord to improve function after neurological trauma. The device will be used to stimulate the cervical spinal cord as participants practice tasks involving upper limb control.
Study NCT05989256 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EndoTool
Description: EndoTool is a vendor based glucose management software
Study NCT05989256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucose management team
Description: comparison group will be services that have not yet implemented EndoTool
Study NCT05989256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care glucose management
Description: providers adjusting insulin and consulting the Glucose Management Team at their discretion
Study NCT06457802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Less Program
Description: The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
Study NCT06369454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg) with 153Sm2O3
Study NCT04391023 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation technique in which a very weak electrical current (2 mA) is applied to the scalp at the beginning of the session and then remains at 0 mA for the duration of the session to control for placebo-like effects. The anode and cathode will both be placed over the cerebellum.
Study NCT04391023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.
Study NCT04391023 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Balance Training
Description: The balance training protocol will include balance training exercises on both compliant (i.e., foam pad and trampoline) and firm surfaces.
Study NCT04391023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 mA Transcranial Direct Current Stimulation
Description: tDCS is a non-invasive brain stimulation technique in which very weak electrical current (2 mA) is applied to the scalp for 20 minutes. The anode and cathode will both be placed over the cerebellum.